Tim J Elliott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7706273/publications.pdf

Version: 2024-02-01

118 papers	7,605 citations	53660 45 h-index	54797 84 g-index
210 all docs	210 docs citations	210 times ranked	7706 citing authors

#	Article	IF	Citations
1	Immunopeptidomic analysis of influenza A virus infected human tissues identifies internal proteins as a rich source of HLA ligands. PLoS Pathogens, 2022, 18, e1009894.	2.1	11
2	Fluctuations in T cell receptor and pMHC interactions regulate T cell activation. Journal of the Royal Society Interface, 2022, 19, 20210589.	1.5	4
3	Introducing Immunotherapy Advances. Immunotherapy Advances, 2021, 1, .	1.2	1
4	The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif. Immunology, 2021, 163, 169-184.	2.0	2
5	Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. Frontiers in Immunology, 2021, 12, 672737.	2.2	8
6	The role of MHC I protein dynamics in tapasin and TAPBPR-assisted immunopeptidome editing. Current Opinion in Immunology, 2021, 70, 138-143.	2.4	13
7	Characterization of the Class I MHC Peptidome Resulting From DNCB Exposure of HaCaT Cells. Toxicological Sciences, 2021, 180, 136-147.	1.4	9
8	Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells. Immunotherapy Advances, 2021, 1, ltaa001.	1.2	5
9	HLA tapasin independence: broader peptide repertoire and HIV control. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28232-28238.	3.3	51
10	Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry, 2019, 294, 20246-20258.	1.6	10
11	Dynamically Driven Allostery in MHC Proteins: Peptide-Dependent Tuning of Class I MHC Global Flexibility. Frontiers in Immunology, 2019, 10, 966.	2.2	41
12	HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC. Cancer Immunology Research, 2019, 7, 1202-1213.	1.6	24
13	Protein Plasticity and Peptide Editing in the MHC I Antigen Processing Pathway. Biochemistry, 2018, 57, 1423-1425.	1.2	5
14	CasPR and the Unfriendly Host?. CRISPR Journal, 2018, 1, 20-22.	1.4	3
15	The partial dissociation of MHC class Iâ€“bound peptides exposes their N terminus to trimming by endoplasmic reticulum aminopeptidase 1. Journal of Biological Chemistry, 2018, 293, 7538-7548.	1.6	19
16	Malaria systems immunology: Plasmodium vivax induces tolerance during primary infection through dysregulation of neutrophils and dendritic cells. Journal of Infection, 2018, 77, 440-447.	1.7	29
17	A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules. Frontiers in Immunology, 2018, 9, 1538.	2.2	35
18	Antigen processing movers and shakers. Nature Chemical Biology, 2018, 14, 747-748.	3.9	1

#	Article	IF	Citations
19	The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer. ELife, 2018, 7, .	2.8	47
20	The Clonal Invariant NKT Cell Repertoire in People with Type 1 Diabetes Is Characterized by a Loss of Clones Expressing High-Affinity TCRs. Journal of Immunology, 2017, 198, 1452-1459.	0.4	9
21	Both rare and common ERAP1 allotypes have distinct functionality defined by polymorphic context and are important in AS association. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1575-E1576.	3.3	5
22	Quantitative and qualitative iNKT repertoire associations with disease susceptibility and outcome in macaque tuberculosis infection. Tuberculosis, 2017, 105, 86-95.	0.8	16
23	CD1b-restricted GEM T cell responses are modulated byMycobacterium tuberculosismycolic acid meromycolate chains. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10956-E10964.	3.3	58
24	Direct evidence for conformational dynamics in major histocompatibility complex class I molecules. Journal of Biological Chemistry, 2017, 292, 20255-20269.	1.6	28
25	Recent advances in Major Histocompatibility Complex (MHC) class I antigen presentation: Plastic MHC molecules and TAPBPR-mediated quality control. F1000Research, 2017, 6, 158.	0.8	34
26	TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway. ELife, 2017, 6, .	2.8	66
27	Bone marrow transplantation for MHC class I deficiency corrects T-cell immunity but dissociates natural killer cell repertoire formation from function. Journal of Allergy and Clinical Immunology, 2016, 138, 1733-1736.e2.	1.5	7
28	Cholesteryl esters stabilize human CD1c conformations for recognition by self-reactive T cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1266-75.	3.3	41
29	Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Molecular Therapy, 2016, 24, 375-384.	3.7	35
30	Ligand Selection and Trafficking for MHC I. , 2016, , 233-240.		0
31	Selector function of MHC I molecules is determined by protein plasticity. Scientific Reports, 2015, 5, 14928.	1.6	69
32	TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst. ELife, 2015, 4, .	2.8	87
33	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	1.1	13
34	Plasticity of empty major histocompatibility complex class I molecules determines peptide-selector function. Molecular Immunology, 2015, 68, 98-101.	1.0	22
35	Reply to Robinson and Brown: It is the combination of ERAP1 allotypes that identifies individuals with Ankylosing Spondylitis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1817-E1817.	3.3	1
36	Structural and Functional Changes of the Invariant NKT Clonal Repertoire in Early Rheumatoid Arthritis. Journal of Immunology, 2015, 195, 5582-5591.	0.4	26

#	Article	IF	Citations
37	Two Polymorphisms Facilitate Differences in Plasticity between Two Chicken Major Histocompatibility Complex Class I Proteins. PLoS ONE, 2014, 9, e89657.	1.1	20
38	Functionally distinct ERAP1 allotype combinations distinguish individuals with Ankylosing Spondylitis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17594-17599.	3.3	90
39	ERAP1 in the pathogenesis of ankylosing spondylitis. Immunologic Research, 2014, 60, 257-269.	1.3	28
40	Distinct Molecular Signature of Human Skin Langerhans Cells Denotes Critical Differences in Cutaneous Dendritic Cell Immune Regulation. Journal of Investigative Dermatology, 2014, 134, 695-703.	0.3	46
41	Common variable immunodeficiency is associated with aÂfunctional deficiency of invariant natural killer T cells. Journal of Allergy and Clinical Immunology, 2014, 133, 1420-1428.e1.	1.5	19
42	Critical Role of Endoplasmic Reticulum Aminopeptidase 1 in Determining the Length and Sequence of Peptides Bound and Presented by HLAâ€“B27. Arthritis and Rheumatology, 2014, 66, 284-294.	2.9	71
43	Peptide-independent stabilization of MHC class I molecules breaches cellular quality control*. Journal of Cell Science, 2014, 127, 2885-97.	1.2	57
44	Naturally Occurring ERAP1 Haplotypes Encode Functionally Distinct Alleles with Fine Substrate Specificity. Journal of Immunology, 2013, 191, 35-43.	0.4	125
45	Induction of Protective Antitumor Immunity through Attenuation of ERAAP Function. Journal of Immunology, 2013, 190, 5839-5846.	0.4	62
46	A Mechanistic Basis for the Co-evolution of Chicken Tapasin and Major Histocompatibility Complex Class I (MHC I) Proteins. Journal of Biological Chemistry, 2013, 288, 32797-32808.	1.6	55
47	Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk. OncoImmunology, 2012, 1, 874-883.	2.1	9
48	Galvanized lunacy. Nature, 2012, 490, 346-347.	13.7	0
49	The pathway of crossâ€presentation is influenced by the particle size of phagocytosed antigen. Immunology, 2012, 136, 163-175.	2.0	52
50	The multidisciplinary management of nonâ€melanoma conchal bowl skin cancer. Australasian Journal of Dermatology, 2012, 53, 229-232.	0.4	3
51	CD8⁺ Tâ€cell crossâ€competition is governed by peptideâ€“MHC class I stability. European Journal of Immunology, 2012, 42, 256-263.	1.6	28
52	Proteasomes, TAP, and Endoplasmic Reticulum-Associated Aminopeptidase Associated with Antigen Processing Control CD4+Th Cell Responses by Regulating Indirect Presentation of MHC Class II-Restricted Cytoplasmic Antigens. Journal of Immunology, 2011, 186, 6683-6692.	0.4	10
53	Tapasin dependence of major histocompatibility complex class I molecules correlates with their conformational flexibility. FASEB Journal, 2011, 25, 3989-3998.	0.2	61
54	A Peptide Filtering Relation Quantifies MHC Class I Peptide Optimization. PLoS Computational Biology, 2011, 7, e1002144.	1.5	39

#	Article	IF	Citations
55	Differential Suppression of Tumor-Specific CD8+ T Cells by Regulatory T Cells. Journal of Immunology, 2010, 185, 5048-5055.	0.4	32
56	Absence of Tapasin Alters Immunodominance against a Lymphocytic Choriomeningitis Virus Polytope. Journal of Immunology, 2010, 184, 73-83.	0.4	30
57	Peptide antagonism as a mechanism for NK cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10160-10165.	3.3	139
58	ERp57 Does Not Require Interactions with Calnexin and Calreticulin to Promote Assembly of Class I Histocompatibility Molecules, and It Enhances Peptide Loading Independently of Its Redox Activity. Journal of Biological Chemistry, 2009, 284, 10160-10173.	1.6	47
59	The Synthesis and inâ€...vivo Evaluation of 2â€²,2â€²â€Difluoro KRN7000. ChemMedChem, 2009, 4, 329-334.	1.6	21
60	Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules. EMBO Journal, 2009, 28, 3730-3744.	3.5	78
61	More Images that Yet Fresh Images Beget. Immunity, 2009, 30, 1-2.	6.6	12
62	Synthesis and inâ€...vitro Evaluation of Î±â€GalCer Epimers. ChemMedChem, 2008, 3, 1061-1070.	1.6	33
63	Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide â€“ MHC classâ€„I complexes. European Journal of Immunology, 2008, 38, 364-369.	1.6	32
64	Molecular machinations of the MHC-I peptide loading complex. Current Opinion in Immunology, 2008, 20, 75-81.	2.4	54
65	Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000. Organic Letters, 2008, 10, 4433-4436.	2.4	30
66	Invariant NKT Cells Promote CD8+ Cytotoxic T Cell Responses by Inducing CD70 Expression on Dendritic Cells. Journal of Immunology, 2008, 180, 4615-4620.	0.4	65
67	The Influence of CD25+ Cells on the Generation of Immunity to Tumour Cell Lines in Mice. Novartis Foundation Symposium, 2008, , 149-157.	1.2	11
68	Folding of an MHC class II-restricted tumor antigen controls its antigenicity via MHC-guided processing. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5983-5988.	3.3	13
69	Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Research, 2007, 9, R46.	2.2	20
70	Direct deprotected glycosylâ€“asparagine ligation. Chemical Communications, 2006, , 1401.	2.2	51
71	The Complex Route to MHC Class I-Peptide Complexes. Cell, 2006, 127, 249-251.	13.5	15
72	The 'chop-and-change' of MHC class I assembly. Nature Immunology, 2006, 7, 7-9.	7.0	5

#	Article	IF	Citations
73	Polymer microarrays: Identification of substrates for phagocytosis assays. Biomaterials, 2006, 27, 5299-5306.	5.7	40
74	The Crystal Structure of H-2Db Complexed with a Partial Peptide Epitope Suggests a Major Histocompatibility Complex Class I Assembly Intermediate. Journal of Biological Chemistry, 2006, 281, 12699-12704.	1.6	32
75	The Inhibitory Receptor NKG2A Determines Lysis of Vaccinia Virus-Infected Autologous Targets by NK Cells. Journal of Immunology, 2006, 176, 1141-1147.	0.4	30
76	The optimization of peptide cargo bound to MHC class I molecules by the peptide-loading complex. Immunological Reviews, 2005, 207, 89-99.	2.8	91
77	Immunogenicity of Calreticulin-Bound Murine Leukemia Virus Glycoprotein gp90. Advances in Experimental Medicine and Biology, 2005, 564, 85-94.	0.8	0
78	Tapasin enhances MHC class I peptide presentation according to peptide half-life. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11737-11742.	3.3	168
79	The processing of antigens delivered as DNA vaccines. Immunological Reviews, 2004, 199, 27-39.	2.8	30
80	Solid-Phase Synthesis of 89 Polyamine-Based Cationic Lipids for DNA Delivery to Mammalian Cells. Chemistry - A European Journal, 2004, 10, 463-473.	1.7	46
81	DNA Transfection Screening from Single Beads. ACS Combinatorial Science, 2004, 6, 753-760.	3.3	14
82	Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. European Journal of Immunology, 2003, 33, 748-759.	1.6	170
83	Assembly and export of MHC class I peptide ligands. Current Opinion in Immunology, 2003, 15, 75-81.	2.4	100
84	The Role of Calnexin and Calreticulin in MHC Class I Assembly. Molecular Biology Intelligence Unit, 2003, , 85-93.	0.2	1
85	Conformational Studies of Oligosaccharides and Glycopeptides:â€‰ Complementarity of NMR, X-ray Crystallography, and Molecular Modelling. Chemical Reviews, 2002, 102, 371-386.	23.0	400
86	Assembly and Antigen-Presenting Function of MHC Class I Molecules in Cells Lacking the ER Chaperone Calreticulin. Immunity, 2002, 16, 99-109.	6.6	217
87	Optimization of the MHC Class I Peptide Cargo Is Dependent on Tapasin. Immunity, 2002, 16, 509-520.	6.6	340
88	Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. European Journal of Immunology, 2002, 32, 3267-3275.	1.6	257
89	The oxidoreductase ERp57 efficiently reduces partially folded in preference to fully folded MHC class I molecules. EMBO Journal, 2002, 21, 2655-2663.	3.5	90
90	Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. , 2002, 32, 3267.		8

#	Article	IF	Citations
91	Glycosylation and the Immune System. Science, 2001, 291, 2370-2376.	6.0	1,487
92	MHC-Restricted T Cell Responses against Posttranslationally Modified Peptide Antigens. Advances in Immunology, 2001, 78, 267-289.	1.1	6
93	Paper alert: Immunology. Current Opinion in Immunology, 2001, 13, 625-634.	2.4	0
94	Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions. Journal of Immunology, 2001, 166, 6720-6727.	0.4	125
95	An Immunodominant MHC Class II-Restricted Tumor Antigen Is Conformation Dependent and Binds to the Endoplasmic Reticulum Chaperone, Calreticulin. Journal of Immunology, 2001, 167, 147-155.	0.4	16
96	DNA Fusion Vaccine Designed to Induce Cytotoxic T Cell Responses Against Defined Peptide Motifs: Implications for Cancer Vaccines. Journal of Immunology, 2001, 167, 1558-1565.	0.4	90
97	Multiple Antigen-Specific Processing Pathways for Activating Naive CD8+ T Cells In Vivo. Journal of Immunology, 2001, 166, 4355-4362.	0.4	85
98	Identification of novel Tapasin polymorphisms and linkage disequilibrium to MHC class I alleles. Immunogenetics, 2000, 52, 9-11.	1.2	15
99	Presentation of Cytosolic Glycosylated Peptides by Human Class I Major Histocompatibility Complex Molecules in Vivo. Journal of Experimental Medicine, 1999, 190, 145-150.	4.2	101
100	Crystal Structures of Two H-2Db/Glycopeptide Complexes Suggest a Molecular Basis for CTL Cross-Reactivity. Immunity, 1999, 10, 63-74.	6.6	121
101	Evidence for successive peptide binding and quality control stages during MHC class I assembly. Current Biology, 1998, 8, 717-721.	1.8	131
102	HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin. European Journal of Immunology, 1998, 28, 3214-3220.	1.6	56
103	Glycan-regulated Antigen Processing of a Protein in the Endoplasmic Reticulum Can Uncover Cryptic Cytotoxic T Cell Epitopes. Journal of Experimental Medicine, 1998, 188, 773-778.	4.2	31
104	A Soluble Major Histocompatibility Complex Class I Peptide-binding Platform Undergoes a Conformational Change in Response to Peptide Epitopes. Journal of Biological Chemistry, 1998, 273, 14200-14204.	1.6	16
105	Transporter Associated with Antigen Processing**This article was accepted for publication on 1 October 1996.. Advances in Immunology, 1997, , 47-109.	1.1	63
106	How does TAP associate with MHC class I molecules?. Trends in Immunology, 1997, 18, 375-379.	7.5	58
107	Point mutations in the Î±2 domain of HLA-A2.1 define a functionally relevant interaction with TAP. Current Biology, 1996, 6, 873-883.	1.8	126
108	Recognition of out-of-frame major histocompatibility complex class I-restricted epitopesin vivo. European Journal of Immunology, 1996, 26, 1175-1179.	1.6	24

#	Article	IF	Citations
109	Tapping into tumours. Nature Genetics, 1996, 13, 139-140.	9.4	8
110	Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. European Journal of Immunology, 1995, 25, 18-24.	1.6	66
111	Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport. European Journal of Immunology, 1995, 25, 554-562.	1.6	123
112	Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. European Journal of Immunology, 1995, 25, 3270-3276.	1.6	74
113	Peptide selection by class I molecules of the major histocompatibility complex. Current Biology, 1993, 3, 854-866.	1.8	71
114	Structural requirements for the peptide-induced conformational change of free major histocompatibility complex class I heavy chains. European Journal of Immunology, 1992, 22, 2085-2091.	1.6	46
115	Short peptides assist the folding of free class I heavy chains in solution. European Journal of Immunology, 1992, 22, 3121-3125.	1.6	19
116	Peptide-induced conformational change of the class I heavy chain. Nature, 1991, 351, 402-406.	13.7	229
117	Naturally processed peptides. Nature, 1990, 348, 195-196.	13.7	29
118	Immunotherapy Advances: One Year On. Immunotherapy Advances, 0, , .	1.2	2